Title:
NOVEL ANTI-LILRB4 ANTIBODIES AND DERIVATIVE PRODUCTS
Document Type and Number:
WIPO Patent Application WO/2021/183839
Kind Code:
A3
Abstract:
The present disclosure provides anti-LILRB4 antibodies or antigen-binding fragments thereof, anti-LILRB4 chimeric antigen receptor protein, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.
More Like This:
| JP2021529776 | Anti-L1CAM antibody and its use |
| JP7235733 | Antibodies that specifically bind to PD-1 and methods of use |
| WO/2023/051656 | BISPECIFIC ANTIBODY AND APPLICATION THEREOF |
Inventors:
SONG AN (US)
HUANG TAO (US)
STAFFORD RYAN (US)
COSTA MARIA JOSE (US)
HONG KYU HEE (US)
BONNANS CAROLINE (US)
ZHOU JIANHUI (US)
ZHOU LI (US)
LI JI (US)
WOODARD J PAUL (US)
LIAO X CHARLENE (US)
HUANG TAO (US)
STAFFORD RYAN (US)
COSTA MARIA JOSE (US)
HONG KYU HEE (US)
BONNANS CAROLINE (US)
ZHOU JIANHUI (US)
ZHOU LI (US)
LI JI (US)
WOODARD J PAUL (US)
LIAO X CHARLENE (US)
Application Number:
PCT/US2021/022029
Publication Date:
March 17, 2022
Filing Date:
March 12, 2021
Export Citation:
Assignee:
IMMUNE ONC THERAPEUTICS INC (US)
International Classes:
C07K16/28; C07K16/46; C07K19/00
Domestic Patent References:
| WO2009155724A2 | 2009-12-30 | |||
| WO2019005634A2 | 2019-01-03 |
Foreign References:
| US20190241655A1 | 2019-08-08 |
Attorney, Agent or Firm:
ZHANG, Yi (US)
Download PDF: